3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Polycystic Ovary Syndrome
7
Neoplasms
6
Breast Neoplasms
6
Vomiting
2
Solid Tumors
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Diabetes Mellitus
2
Weight Gain
1
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Skin Toxicity
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Premature Birth
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pre-Eclampsia
1
Polycythemia Vera
1
Parathyroid Neoplasms
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Nausea
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Interventions
fludarabine phosphate
38
Cyclophosphamide
37
Peripheral Blood Stem Cell Transplantation
32
Busulfan
28
Tacrolimus
26
Whole-Body Irradiation
20
Mycophenolic Acid
19
Methotrexate
17
Antilymphocyte Serum
17
ruxolitinib
16
fludarabine
14
Filgrastim
13
Cyclosporine
12
Melphalan
11
Radiotherapy
9
Etoposide
9
thymoglobulin
8
Psychiatric Rehabilitation
8
Prednisone
8
Methylprednisolone
8
Cytarabine
6
Cord Blood Stem Cell Transplantation
6
Thiotepa
5
Sirolimus
5
Imatinib Mesylate
5
Flow Cytometry
5
Azacitidine
5
Alemtuzumab
5
sargramostim
4
merphos
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Primary Myelofibrosis
×
Tablets
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled